Inactive Instrument
Intervacc AB Share Price Nasdaq Stockholm
Stocks
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - SEK | - |
|
| 05-22 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 05-15 | Sweden's Intervacc Elects New Chair | MT |
| Market Cap | 443M 45.51M 39.92M 36.85M 34.06M 64.55M 4.36B 65.84M 172M 2.13B 171M 167M 7.4B | P/E 2026 * |
-5.91x | P/E 2027 * | -5.91x |
|---|---|---|---|---|---|
| Enterprise Value | 350M 35.96M 31.54M 29.12M 26.91M 51M 3.44B 52.02M 136M 1.68B 135M 132M 5.85B | EV / Sales 2026 * |
19.8x | EV / Sales 2027 * | 12.6x |
| Free-Float |
80.66% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 04/02/2026 | |
Jan Persson
DFI | Director of Finance/CFO | - | 05/02/2020 |
Andrew Waller
CTO | Chief Tech/Sci/R&D Officer | - | 10/06/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Billbäck
CHM | Chairman | 56 | 12/05/2026 |
| Director/Board Member | 72 | 31/12/2023 | |
| Director/Board Member | 68 | 31/12/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | -3.22% | +71.74% | +127.13% | 56.71B | |
| -2.45% | -7.83% | +63.92% | +83.15% | 51.3B | |
| +0.97% | +5.39% | +21.92% | +476.57% | 25.26B | |
| -0.25% | -4.05% | -16.27% | -12.88% | 23.65B | |
| +3.93% | +7.11% | +44.20% | -1.96% | 18.69B | |
| +2.01% | +2.80% | +40.47% | -24.60% | 17.71B | |
| -6.84% | +4.81% | +201.88% | +348.11% | 17.7B | |
| -0.92% | +8.90% | +38.48% | - | 14.26B | |
| +1.75% | +1.88% | +29.11% | +198.37% | 14.1B | |
| Average | -0.20% | +3.18% | +55.05% | +149.24% | 26.6B | |
| Weighted average by Cap. | -0.47% | +1.64% | +56.78% | +140.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.7M 1.82M 1.59M 1.47M 1.36M 2.58M 174M 2.63M 6.88M 85.2M 6.83M 6.68M 296M | 30.05M 3.09M 2.71M 2.5M 2.31M 4.38M 296M 4.47M 11.68M 145M 11.59M 11.34M 502M |
| Net income | -80.8M -8.3M -7.28M -6.72M -6.21M -11.77M -795M -12.01M -31.39M -389M -31.17M -30.49M -1.35B | -83.65M -8.59M -7.54M -6.96M -6.43M -12.19M -823M -12.43M -32.5M -403M -32.27M -31.56M -1.4B |
| Net Debt | -93M -9.55M -8.38M -7.74M -7.15M -13.55M -915M -13.82M -36.14M -448M -35.88M -35.09M -1.55B | -63M -6.47M -5.68M -5.24M -4.84M -9.18M -620M -9.36M -24.48M -303M -24.3M -23.77M -1.05B |
Employees
-
Calendar
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
